Understanding the immunoangiostatic CXC chemokine network

Cardiovascular Research

Volumn 78, Issue 2, 2008, Pages 250-256

  Balestrieri, Maria Luisa ^a   Balestrieri, Antonio ^a   Mancini, Francesco Paolo ^b   Napoli, Claudio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

Author keywords

Chemokines; CXCR3; Immunoangiostasis

Indexed keywords

ALPHA CHEMOKINE; ARGININE; CARBON TETRACHLORIDE; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; CYSTEINE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMIC ACID; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; LEUCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL INJURY; CANCER INHIBITION; CARCINOGENESIS; GROWTH INHIBITION; HUMAN; IMMUNOREGULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW;

ANGIOGENIC PROTEINS; ANGIOSTATIC PROTEINS; ANIMALS; CHEMOKINES, CXC; ENDOTHELIAL CELLS; HUMANS; IMMUNITY, CELLULAR; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CXCR; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION;

EID: 42349113830     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn029     Document Type: Review

References (70)

1. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;4443:516-518.
2. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971;21:1182-1186.
3. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003;2:159-167.
4. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;5089:1798-1801.
5. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005;6:593-609.
6. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 2007;8:1242-1250.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996;3:353-364.
8. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;8812:145-146.
9. Colobran R, Pujol-Borrell R, Armengol MP, Juan M. The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clin Exp Immunol 2007;2:208-217.
10. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
11. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001;2:95-101.
12. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;6:768-778.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
14. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M et al. A distinct and unique transcriptional program expressed by tumour-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-2122.
15. Howard OM, Galligan CL. An expanding appreciation of the role chemokine receptors play in cancer progression. Curr Pharm Des 2004;19:2377- 2389.
16. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006;8:962-974.
17. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787-820.
18. Jin H, Hayes GL, Darbha NS, Meyer E, LiWang PJ. Investigation of CC and CXC chemokine quaternary state mutants. Biochem Biophys Res Commun 2005;2:987-999.
19. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003;100:1885-1890.
20. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;1:1-8.
21. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;45:27348-27357.
22. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004;2:95-104.
23. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006;1:139-149.
24. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 2000;6:759-769.
25. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7:243.
26. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;3:149-161.
27. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;24:7203-7206.
28. Kijowski J, Baj-Krzyworzeka M, Majka M, Reca R, Marquez LA, Christofidou-Solomidou M et al. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001;5:453-466.
29. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999;4:1125-1135.
30. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006;79:639-651.
31. tde Nigris F, Balestrieri ML, Williams-Ignarro S, D'Armiento FP, Lerman LO, Byrns RE et al. Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hindlimb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. J Cardiovasc Pharmacol 2007;50:424-433.
32. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumour cells and their microenvironment. Blood 2006;107:1761-7176.
33. Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002;8:1250-1256.
34. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;6824:50-56.
35. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;12:1676-1686.
36. Strahm B, Durbin AD, Sexsmith E, Malkin D. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2008;25:1-10.
37. Woo SU, Bae JW, Kim CH, Lee JB, Koo BW. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 2008; 15:281-285.
38. Jones J, Marian D, Weich E, Engl T, Wedel S, Relja B et al. CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res 2007;313:4051-4065.
39. Richard CL, Lowthers EL, Blay J. 15-Deoxy-Delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma-and NFkappaB-mediated pathways. Exp Cell Res 2007;313:3446-3458.
40. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;8:1201-1212.
41. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;6:447-454.
42. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997;5:554-562.
43. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumourigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996;12:2792-2802.
44. Lentsch AB. CXC chemokines and prostate cancer: growth regulators and potential biomarkers. Future Oncol 2006;5:651-658.
45. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005;8:5351-5357.
46. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in C. Proc Natl Acad Sci USA 1998;16:9448-9453.
47. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;6685:591-594.
48. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 2000;6:1937-1950.
49. Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumour responses in a lung cancer model. J Immunol 2003;12:6457-6465.
50. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 2004;22:8262-8270.
51. Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 2005;1:67-74.
52. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;11:1537- 1549.
53. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998;11:3696-3705.
54. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;7:436-445.
55. Rollins BJ. Chemokines. Blood 1997;3:909-928.
56. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;1:53-63.
57. Yang J, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004;6:846-855.
58. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005;3:261-268.
59. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;3:963-969.
60. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-128.
61. Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumour immunity. Gene Ther 2001;4:282-290.
62. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S et al. CXCR3/ CXCR3 ligand biological axis impairs RENCA tumour growth by a mechanism of immunoangiostasis. J Immunol 2006;3:1456-1464.
63. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;4:746-754.
64. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999;7:3840-3850.
65. Kelsen SG, Aksoy MO, Yang Y, Shahabuddin S, Litvin J, Safadi F et al. The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L584-L591.
66. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006;66:9509-9518.
67. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumour responses in vivo. J Immunol 2000;9:4558-4563.
68. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK et al. SLC/ CCL21-mediated anti-tumour responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2003;2:22.
69. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumour. J Immunol 1998;2:927-932.
70. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006;4:265-279.